an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.
Company profile
Ticker
AMRX
Exchange
Website
CEO
Chirag K. Patel
Employees
Fiscal year end
Industry (SIC)
Former names
Atlas Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
Amneal Pharmaceuticals, Inc. • Amedra Pharmaceuticals LLC • Amneal Healthcare Private Ltd. • Amneal Complex Products, Research LLC • Amneal EU, Limited • Amneal Ireland Limited • Amneal Oncology Private Limited • Amneal Biosciences Private Limited • Amneal Pharma Germany GmbH • Amneal Pharmaceuticals Private Limited ...
AMRX stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
1 Mar 24
8-K
Results of Operations and Financial Condition
10 Jan 24
CERT
Certification of approval for exchange listing
26 Dec 23
25
Voluntary exchange delisting
26 Dec 23
8-A12B
Registration of securities on exchange
26 Dec 23
8-K
Amneal Announces Move to Nasdaq
15 Dec 23
8-K/A
Financial Statements and Exhibits
15 Dec 23
Transcripts
AMRX
Earnings call transcript
2023 Q4
1 Mar 24
AMRX
Earnings call transcript
2023 Q3
7 Nov 23
AMRX
Earnings call transcript
2023 Q2
4 Aug 23
AMRX
Earnings call transcript
2023 Q1
5 May 23
AMRX
Earnings call transcript
2022 Q4
2 Mar 23
AMRX
Earnings call transcript
2022 Q3
4 Nov 22
AMRX
Earnings call transcript
2022 Q2
5 Aug 22
AMRX
Earnings call transcript
2022 Q1
4 May 22
AMRX
Earnings call transcript
2021 Q4
2 Mar 22
AMRX
Earnings call transcript
2021 Q3
3 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 95.61 mm | 95.61 mm | 95.61 mm | 95.61 mm | 95.61 mm | 95.61 mm |
Cash burn (monthly) | 6.33 mm | 23.67 k | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 42.23 mm | 158.03 k | n/a | n/a | n/a | n/a |
Cash remaining | 53.37 mm | 95.45 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 8.4 | 4033.1 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
33.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 144 |
Opened positions | 32 |
Closed positions | 16 |
Increased positions | 54 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 419.47 bn |
Total shares | 101.90 mm |
Total puts | 1.80 k |
Total calls | 101.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
FOSUF Fosun International | 21.52 mm | $90.82 bn |
Vanguard | 13.55 mm | $57.17 bn |
TPG GP A | 12.33 mm | $52.03 bn |
BLK Blackrock | 8.03 mm | $33.90 bn |
Rubric Capital Management | 4.02 mm | $16.98 bn |
Neuberger Berman | 3.83 mm | $16.18 bn |
Citadel Advisors | 2.69 mm | $11.35 bn |
Eversept Partners | 2.64 mm | $11.16 bn |
STT State Street | 2.34 mm | $9.85 bn |
Geode Capital Management | 2.32 mm | $9.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Konidaris Tasos | Class A Common Stock | Payment of exercise | Dispose F | No | No | 5.31 | 30,790 | 163.49 k | 527,316 |
12 Mar 24 | Konidaris Tasos | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 87,720 | 0.00 | 558,106 |
12 Mar 24 | Konidaris Tasos | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 87,720 | 0.00 | 0 |
4 Mar 24 | Jason B. Daly | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 287,038 | 0.00 | 287,038 |
4 Mar 24 | Jason B. Daly | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 143,519 | 0.00 | 143,519 |
4 Mar 24 | Konidaris Tasos | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 351,852 | 0.00 | 351,852 |
4 Mar 24 | Konidaris Tasos | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 175,926 | 0.00 | 175,926 |
4 Mar 24 | Andrew S Boyer | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 305,556 | 0.00 | 305,556 |
4 Mar 24 | Andrew S Boyer | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 152,778 | 0.00 | 152,778 |
4 Mar 24 | Nikita Shah | RSU Class A Common Stock | Grant | Acquire A | No | No | 0 | 287,038 | 0.00 | 287,038 |
News
Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine
16 Apr 24
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
5 Apr 24
Amneal Receives FDA Approval For Ciprofloxacin And Dexamethasone Otic Suspension
25 Mar 24
Piper Sandler Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $8
21 Mar 24
Goldman Sachs Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $6.25
4 Mar 24
Press releases
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
16 Apr 24
Amneal to Report First Quarter 2024 Results on May 3, 2024
10 Apr 24
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
25 Mar 24
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
1 Mar 24
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
27 Feb 24